BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

NicOx SA (COX.PA): Patient Recruitment Completed by Bausch & Lomb in Glaucoma Study


11/28/2011 9:31:36 AM

SOPHIA ANTIPOLIS, FRANCE--(Marketwire - November 28, 2011) -



PRESS RELEASE

NicOx: Patient recruitment completed by Bausch + Lomb in glaucoma study

www.nicox.com

NicOx S.A. (NYSE Euronext Paris: COX) today announced that the ongoing phase 2b study of BOL-303259-X, conducted by its partner Bausch + Lomb, has finished recruitment. Bausch + Lomb anticipates that the study will be completed by the end of December 2011, with preliminary results expected in the first quarter of 2012.

BOL-303259- is an NO-donating prostaglandin F2-alpha analog which is thought to lower intraocular pressure (IOP) through a dual mechanism of action. The ongoing study is intended to identify the most effective dose of BOL- 303259-X, administered in the evening to patients with open-angle glaucoma or ocular hypertension, for the reduction of IOP.

About NicOx

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company focused on the research, development and future commercialization of drug candidates. NicOx is applying its proprietary nitric oxide-donating R&D platform to develop an internal portfolio of New Molecular Entities (NMEs) for the potential treatment of inflammatory, cardio-metabolic and ophthalmological diseases.

The Company's pipeline includes several nitric oxide-donating NMEs, which are in development internally and with partners, who include Merck (known as MSD outside the United States and Canada), Bausch + Lomb, and Ferrer.

NicOx S.A. is headquartered in France and is listed on Euronext Paris (Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on NicOx's business are presented in the 4(th) chapter of the « Document de référence, rapport financier annuel et rapport de gestion 2010 » filed with the French Autorité des Marchés Financiers (AMF) on February 25, 2011 and available on NicOx's website (www.nicox.com) and on the AMF's website (www.amf-france.org).

NICOX: Patient recruitment completed by Bausch + Lomb in glaucoma study: http://hugin.info/143509/R/1566780/486563.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: NICOX via Thomson Reuters ONE

[HUG#1566780]


CONTACTS
NicOx
Gavin Spencer
Vice President Business Development
Tel +33 (0)4 97 24 53 00
Email Contact
www.nicox.com

Media Relations
FTI Consulting
Jonathan Birt
Tel : +44 (0)20 7269 7205
Email Contact

NicOx S.A.
Les Taissounieres
Bat HB4
1681 route des Dolines - BP313
06906 Sophia Antipolis Cedex - France
Tel: +33 (0)4 97 24 53 00
Fax: +33 (0)4 97 24 53 99



Read at BioSpace.com

   
Glaucoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES